




Figure 1A




Figure 1B




Figure 2




Figure 3A




Figure 3B




Figure 4




Figure 5A




Figure 5B




Figure 5C




Figure 6

GAXC031 cell based affinity test for humanized antibodies




Figure 7A

No.	antibody	Max MFI	EC50(nM)
1	hIgG1	—	—
2	IMAB362	2487.1	452.2
3	Ab15-chimeric	36915.5	25.11
4	Ab15-VH3xVLN1	36812.3	28.63
5	Ab15-VHN1xVL2	36752.3	32.25
6	Ab10-chimeric	35931.4	49.23
7	Ab10-VHN1xVLN1	34828.8	43.84
8	Ab10-VH3xVLN1	35183	60.89
9	Ab17-chimeric	29685	47.02
10	Ab17-VH5xVLN1	30874.1	48.89
11	Ab17-VH1xVLN1	27492.7	43.68

Figure 7B




Figure 8A





Figure 8B

Cell based binding affinity on SNU620 cells



	Ab15	Ab10	Ab17	IMB362
EC50	5.317	5.538	10.79	~ 7537

Figure 8C




Figure 9A




Figure 9B




Figure 9C




Figure 9D




Figure 9E





Figure 9F

Entry	Kinetics model	Immobilized ligand	Analyte 1 Solution	Kinetics Chi ² (RU ²)	k _a (1/Ms)	k _d (1/s)	KD (M)
1	1:1 binding	200ug/ml CLDN18.2-biotin	Ab15- VH3xVLN1	5.03E-01	5.26E+05	3.72E-07	7.07E-13
2	1:1 binding	200ug/ml CLDN18.2-biotin	Ab15- VHN1xVL2	6.19E-01	5.69E+05	5.35E-06	9.40E-12
3	1:1 binding	200ug/ml CLDN18.2-biotin	Ab10- VHN1xVLN1	6.03E-01	5.47E+05	7.57E-05	1.39E-10
4	1:1 binding	200ug/ml CLDN18.2-biotin	Ab10- VH3xVLN1	3.48E-01	4.89E+05	2.16E-04	4.41E-10
5	1:1 binding	200ug/ml CLDN18.2-biotin	Ab17- VH5xVLN1	1.47E-01	5.26E+05	2.42E-04	4.60E-10
6	1:1 binding	200ug/ml CLDN18.2-biotin	Ab17- VH1xVLN1	1.03E-01	4.23E+05	2.09E-04	4.95E-10

Figure 9G


ADC cytotoxicity assay on CHOK1-CLDN18.2 cells



	Ab15-chimeric-vc-MMAE	Ab15-VH3xVLN1-vc-MMAE	Ab15-VHN1xVL2-vc-MMAE
IC50	7.750	6.930	5.065

Figure 10A


ADC cytotoxicity assay on CHOK1-CLDN18.2 cells



	Ab17-chimeric-vc-MMAE	Ab17-VH5xVLN1-vc-MMAE	Ab17-VH1xVLN1-vc-MMAE
IC50	7.535	6.686	8.258

Figure 10B


ADC cytotoxicity assay on CHOK1-CLDN18.2 cells



	Ab10-chimeric-vc-MMAE	Ab10-VHN1xVLN1-vc-MMAE	Ab10-VH3xVLN1-vc-MMAE
IC50	2.711	2.865	1.988

Figure 10C

ADC cytotoxicity assay on CHOK1-CLDN18.2 cells



IC50	Ab15-VHN1xVL2-vc-MMAE	Ab10-VH3xVLN1-vc-MMAE	Ab17-VH1xVLN1-vc-MMAE	IgG-vc-MMAE
	4.033	6.418	8.614	266.8

Figure 10D




Figure 10E

	GAXC031, 2000/well, 120h	
Samples ID.	Max inhibition%	IC50 (nM)
hIgG1-vc-MMAE	63.94	-
Ab15-chimeric-vc-MMAE	96.89	0.20
Ab15-VH3xVLN1-vc-MMAE	97.28	0.25
Ab15-VHN1xVL2-vc-MMAE	97.11	0.25
Ab10-chimeric-vc-MMAE	97.49	0.36
Ab10-VHN1xVLN1-vc-MMAE	97.28	0.41
Ab10-VH3xVLN1-vc-MMAE	97.05	0.46
Ab17-chimeric-vc-MMAE	96.69	0.58
Ab17-VH5xVLN1-vc-MMAE	96.39	0.51
Ab17-VH1xVLN1-vc-MMAE	96.47	0.53

Figure 10F




Figure 11A




Figure 11B




Figure 12A




Figure 12B




Figure 12C




Figure 12D




Figure 12E




Figure 12F




Figure 12G




Figure 12H




Figure 12I




Figure 12J




Figure 12K




Figure 13A




Figure 13B




Figure 13C




Figure 13D

Group 3, Ab15-VHN1xVL2-VC-MMAE,3mg/kg i.v.




Figure 13E

Group 4, Ab10-VH-N1xVL-N1-VC-MMAE,3mg/kg i.v.




Figure 13F

Group 5, Ab10-VH3xVL1-VC-MMAE,3mg/kg i.v.




Figure 13G

Group 6, Ab17-VH5xVL-N1-VC-MMAE,3mg/kg i.v.




Figure 13H

Group 7, Ab17-VH1xVL-N1-VC-MMAE,3mg/kg i.v.




Figure 13I

Group 8, Ab10-chimeric-VC-MMAE,3mg/kg i.v.




Figure 13J

Group 9, Ab15-chimeric-VC-MMAE,3mg/kg i.v.




Figure 13K

Group 10, Ab17-chimeric-VC-MMAE,3mg/kg i.v.




Figure 13L




Figure 13M